BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$1.63 USD
-0.06 (-3.55%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $1.62 -0.01 (-0.61%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
BioXcel Therapeutics, Inc. [BTAI]
Reports for Purchase
Showing records 41 - 60 ( 109 total )
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dementia Clinical Development Clarity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL701 Orphan Drug Status Granted in Soft Tissue Sarcoma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive BXCL501 Clinical Dementia Data; Raising PT to $185
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Department of Defense Grant Program for BXCL501 in PTSD; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Financials; Clinical and Regulatory Catalysts Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Meeting Paves Path to BXCL501 Regulatory Submission; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Cleared to Advance Into Testing for Delirium; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Higher Dose Cohort in TRANQUILITY Trial; 2Q20 Financials; Lowering PT to $175
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Passes Phase 3 Test With Flying Colors; Raising PT to $200
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Delirium and Agitation Compassionate Use Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Patent Allowance Widens BXCL501 Commercial Window; Raising PT to $120
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Conversation With Chief Commercial Officer Catalyzes Confidence; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Chief Development Officer Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Amply Qualified Chief Commercial Officer Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
RELEASE Trial Patient Enrollment Initiation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Pivotal Program Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clear Clinical Progress; Data Catalysts Imminent; 1Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R